

REMARKS

Reconsideration and withdrawal of the rejections of the application are respectfully requested in view of the amendments and remarks herein. The Examiner is thanked for determining that claims 40-42, in so far as they read upon the compound carbenoxolone, are allowable.

I. STATUS OF THE CLAIMS AND FORMAL MATTERS

Claims 40-43 are now pending. Claims 40-42 have been amended, and new claim 43 has been added, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents.

No new matter is added.

It is submitted that these claims are and were in full compliance with the requirements of 35 U.S.C §112. In addition, the amendment and remarks herein are not made for the purpose of patentability within the meaning of 35 U.S.C. §§101, 102, 103 or 112; but rather the amendments and remarks herein are made simply for clarification and to round out the scope of protection to which Applicants are entitled. Support for the amended and new claims is found throughout the specification and in the claims as originally filed. Specifically, support for new claim 43 can also be found in previously filed claim 40. The addition of claim 43 has been made solely for the purpose of removing the phrase “such as” from claim 40.

II. THE OBJECTIONS TO THE SPECIFICATION ARE OVERCOME

The Office Action objected to the specification as lacking the alternative spelling for “disulphiram”, containing a hyperlink, misspellings, errors in punctuation, as well as having other informalities. The objection is traversed.

In so far as the Office Action requested that the specification be amended to incorporate any additional material necessary from UK 9905510.5 and PCT/GB00/00876, Applicants do not consider such amendment necessary at the present time and have therefore not included such an amendment herein. Applicants reserve the right to make such an amendment in any application filed that claims priority to the present application, or in the present application through a reissue or reexamination procedure if necessary.

The Amendment herein has corrected those remaining items identified in the Office Action, rendering the objection moot. Reconsideration and withdrawal of the objection is respectfully requested.

III. THE ART REJECTIONS ARE OVERCOME

Claims 40-42 are rejected under 35 U.S.C. §102(b) allegedly being anticipated by Ku et al. (U.S. Patent No. 4,870,101) to the extent the claims read on disulphiram and psoriasis. The rejection is respectfully traversed.

The Amendments herein have limited the claims to solely read upon the compound carbenoxolone. As the pending claims no longer read upon disulphiram, the rejection is moot. Consequently, reconsideration and withdrawal of the rejection under 35 U.S.C. §102(b) is respectfully requested.

REQUEST FOR INTERVIEW


If any issue remains as an impediment to allowance, an interview with the Examiner is respectfully requested, prior to issuance of any paper other than a Notice of Allowance; and, the Examiner is respectfully requested to contact the undersigned to arrange a mutually convenient time and manner for such an interview.

CONCLUSION

For the reasons stated above, applicant respectfully requests a favorable reconsideration of the application, reconsideration and withdrawal of the rejections of and objections to the instant application, and prompt issuance of a Notice of Allowance.

Respectfully submitted,
FROMMER LAWRENCE & HAUG LLP

By:


Thomas J. Kowalski
Reg. No. 32,147
Angela M. Collison
Reg. No. 51,107
Tel. (212) 588-0800
Fax (212) 588-0500